Tivantinib is a potent bisindolylmaleimide kinase inhibitor that selectively targets the dephosphorylated MET receptor tyrosine kinase to inhibit tumor growth. Primarily investigated for its therapeutic… Read more
Tivantinib is a potent bisindolylmaleimide kinase inhibitor that selectively targets the dephosphorylated MET receptor tyrosine kinase to inhibit tumor growth. Primarily investigated for its therapeutic potential in treating solid tumors characterized by MET overexpression, such as non-small cell lung cancer and glioblastoma, this compound requires rigorous analytical oversight. To support this, our collection of Tivantinib reference standards includes the active pharmaceutical ingredient alongside its pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope-labelled compounds. Pharmaceutical laboratories utilize these high-quality materials for precise impurity profiling, method validation, and ongoing quality control of the drug substance. By providing essential tools for the identification and quantification of related substances, these reference compounds ensure compliance with regulatory standards and facilitate the development of accurate analytical methods throughout the drug development lifecycle.